QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against UniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Pivotal Study and its implications for the BLA submission timeline [4][6]. Group 1: Allegations Against UniQure - The complaint alleges that UniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design [6]. - It is claimed that the company downplayed the likelihood of needing to delay its BLA submission due to additional studies [6]. - The statements made by the defendants about the company's business and prospects are said to lack a reasonable basis [6]. Group 2: Impact of FDA Disclosure - On November 3, 2025, UniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous representations [7]. - Following this disclosure, UniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [8]. Group 3: Legal Proceedings - Investors who suffered losses in UniQure are encouraged to contact Faruqi & Faruqi to discuss their legal options, with a deadline of April 13, 2026, to seek the role of lead plaintiff in the class action [4][9]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. Group 4: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding UniQure's conduct [10].